DeCure for Microcephaly 24, primary, autosomal recessive
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for microcephaly 24, primary, autosomal recessive — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMicrocephaly 24, primary, autosomal recessive maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for microcephaly 24, primary, autosomal recessive is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Autosomal recessive primary microcephaly (MCPH) is a genetically heterogeneous neurodevelopmental disorder defined by a significantly reduced head circumference at birth and intellectual disability. Inconsistent features include hyperactivity, expressive speech disorder, and epilepsy. A 2017 overview provides no treatment data, only a clinical summary. A 1992 report on three sibling pairs with microcephaly and severe neurological impairment, along with other sibling pairs from the literature, illustrates that microcephaly with spasticity and severe mental retardation can also follow autosomal recessive inheritance. The authors looked for specific morphological features to identify these genetic forms for counselling but found no characteristic abnormalities.
A 1995 description of five affected siblings in one family reports marked microcephaly, intractable seizures, quadriplegia, and profound mental retardation. The recurrence risk in such families may be high, and the authors stress the importance of genetic counselling. No treatment or intervention is mentioned. A 2017 study identifies mutations in KIF14, encoding kinesin-like protein KIF14, as a cause of both primary and syndromic microcephaly. The majority of genes implicated in these disorders encode proteins involved in cell division, many localised at the centrosome. No therapeutic trial, drug, or outcome data are presented in any of these abstracts.
No drug, no trial, no survival or response rates are reported across these four abstracts. What is missing is any clinical trial, any tested intervention, any patient stratification by genotype, and any funding directed toward treatment development for this group of disorders.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Neuropediatrics · 2017 · 91 citations
Autosomal Recessive Primary Microcephaly (MCPH): An Update
AbstractAutosomal recessive primary microcephaly (MCPH; MicroCephaly Primary Hereditary) is a genetically heterogeneous neurodevelopmental disorder characterized by a significantly reduced head circumference present already at birth and intellectual disability. Inconsistent features include hyperactivity, an expressive speech disorder, and epilepsy. Here, we provide a brief overview on this rare disorder pertinent for clinicians.
Autosomal Recessive Microcephaly with Severe Psychomotor Retardation
AbstractAutosomal recessive microcephaly has long been recognized in association with normal early motor development and mild to severe mental retardation. We report three sibling pairs with microcephaly and severe neurological impairment. These cases and other sibling pairs reported in the literature illustrate that microcephaly with spasticity and severe mental retardation may also have autosomal recessive inheritance. Furthermore this severely affected group of patients forms a significant proportion of cases of genetic microcephaly. We looked for specific morphological features to identify these forms of genetic microcephaly for genetic counselling, but failed to find characteristic abnormalities among our group of patients.
Familial microcephaly with severe neurological deficits: a description of five affected siblings
AbstractAutosomal recessive microcephaly is usually characterized by normal developmental milestones and minor neurological deficits. In this report, we describe five siblings in one family with marked microcephaly, intractable seizures, quadriplegia and profound mental retardation. The recurrence risk of microcephaly when associated with devastating neurological deficits, as exemplified by this family, may be high and in such cases, the role of appropriate genetic counseling is of utmost importance.
Mutations in KIF14, Encoding Kinesin-Like Protein KIF14, Cause Primary and Syndromic Microcephaly
AbstractPrimary microcephaly (small head) is a neurodevelopmental disorder characterized by a reduction in the size of the cerebral cortex accompanied with mild to moderate intellectual disability. This condition is observed either as an isolated form referred to as autosomal recessive primary microcephaly (MCPH) or in combination with additional features like growth retardation, renal and cranio-facial abnormalities or others subsumed under syndromic microcephaly. Both MCPH and syndromic microcephaly are heterogeneous disorders caused by mutations of many different genes. The majority of these genes encode proteins implicated in cell division and many of them have been localized at the centrosome.
Neuropathologic findings in patients with primary autosomal recessive microcephaly
AbstractAutosomal recessive primary microcephaly (MCPH, syn. Microcephalia vera) is a rare, genetically heterogeneous disease, in which patients exhibit microcephaly by the 32nd week of gestation. Genetic causes of MCPH subtypes 1–6 include mutations in genes encoding microcephalin (MCPH1), cyclin dependent kinase 5 regulatory associated protein 2 CDK5RAP2 (MCPH3), abnormal spindle-like, microcephaly associated ASPM (MCPH5), centromeric protein J CENPJ (MCPH6) as well as linkage to the two loci 19q13.1–13.2 (MCPH2) and 15q15-q21 (MCPH4). Severe microcephaly is characterized by a significantly reduced occipito-frontal head circumference (OCF) of more than three standard deviations below the mean for age, sex, and ethnicity. Microcephaly correlates closely with reduced brain volume and mental retardation, but patients with MCPH typically do not have further neurological findings. Imaging studies show brains of normal architecture but of reduced size. The latter is particularly evident in the cerebral cortex, which shows a simplified cerebral cortex structure, and there is also a slightly reduced white matter volume. Individual patients with MCPH provide evidence of periventricular neuronal heterotopias suggesting neuronal migration defects. It is not known whether the brain pathology in patients with MCPH is the result of defective cell proliferation/differentiation, cell migration and/or increased cell death. Neuropathological studies, which are rare and were performed at a time when a genetic diagnosis could not be performed, are thus highly warranted. Here, we summarize current knowledge on histological findings in MCPH patients. Infants with Microcephalia vera exhibited a significantly reduced brain volume with an almost preserved convolution pattern and no myelination disturbances. Cytoarchitectonic anomalies, seen predominantly in the first two cortical layers, included the appearance of compact cell clusters in the second layer. This can be interpreted as being indicative of a proliferation/differentiation and/or migration defect.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
